Boceprevir: A protease inhibitor for the treatment of chronic hepatitis C;Boceprevir: Un inhibidor de proteasa para el tratamiento de hepatitis C crónica

Annals of Pharmacotherapy

Volumn 45, Issue 9, 2011, Pages 1085-1093

  Foote, Bryce S ^a   Spooner, Linda M ^a   Belliveau, Paul P ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Boceprevir; Hepatitis C virus; SCH 503034; Victrelis

Indexed keywords

BOCEPREVIR; ERYTHROPOIETIN; PEGINTERFERON ALPHA2B; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; VIRUS RNA;

ANEMIA; CHRONIC HEPATITIS; DRUG CAPSULE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MONOTHERAPY; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RASH; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VIRUS HEPATITIS; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; VIRAL NONSTRUCTURAL PROTEINS;

EID: 80052456662     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P744     Document Type: Review

References (31)

1. Sexually transmitted diseases treatment guidelines, 2010: hepatitis C. Centers for Disease Control and Prevention. http://www.cdc.gov (ac-cessed 2010 Sep 1).
2. Hepatitis C. World Health Organization. www.who.org (accessed 2010 Sep 1).
3. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74. DOI 10.1002/hep.22759
4. Verna EC, Brown RS Jr. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006;10:919-40. DOI 10.1016/j.cld.2006.08.012
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347: 975-82. DOI 10.1056/NEJMoa020047
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358: 958-65. DOI 10.1016/S0140-6736(01)06102-5
7. Lange CM, Sarrazin C, Zeuzem S. Specifically targeted anti-viral therapy for hepatitis C-a new era in therapy. Aliment Pharmacol Ther 2010; 32:14-28. DOI 10.1111/j.1365-2036.2010.04317.x
8. Product information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck & Co., Inc., May 2011.
9. Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006;50:1013-20. DOI 10.1128/AAC.50.3.1013-1020.2006
10. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939-45. DOI 10.1038/nature04078
11. Li, K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005;102:2992-7. DOI 10.1073/pnas.0408824102
12. Zhang J, Gupta S, Rouzier R, Calzetta A, Cutler D. Single dose pharmacokinetics of a novel hepatitis C protease inhibitor, SCH 503034, in an oral capsule formulation (abstract 862). Presented at: 56th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco: Hepatology 2005;42:535A. DOI 10.1002/hep.20926
13. Zeuzem S, Sarrazin C, Rouzier R, et al. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN-α) (abstract 94). Presented at: 56th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco: Hepatology 2005;42:233A-4A. DOI 10.1002/hep.20923
14. Zeuzem S, Sarrazin C, Wagner F, et al. Combination therapy with the HCV protease inhibitor, SCH 503034, plus peg-intron in hepatitis C genotype-1 peg-intron non-responders: Phase IB results (abstract 201). Presented at: 56th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco: Hepatology 2005;42:276A-7A. DOI 10.1002/hep.20923
15. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132:1270-8. DOI 10.1053/j.gastro.2007.01.041
16. Preston, R, Alonso, A, Feely, W, et al. SCH 503034, an oral HCV protease inhibitor, is well-tolerated in patients with varying degrees of hepatic im-pairment (abstract 545). Presented at: 42nd Annual Meeting of the European Association for the Study of the Liver. Barcelona, 2007:S207. Hepatology 2007;46:S207 DOI 10.1016/S0168-8278(07)62143-6.
17. Njoroge F. Discovery of SCH 503034, a selective, potent HCV NS3 protease inhibitor with oral bioavailability: potential therapeutic agent for treating hepatitis C viral infection (abstract 252). Presented at: 230th American Chemical Society National Meeting, Washington DC.
18. Ghosal A, Yuan Y, Tong W, et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011;39:510-21.DOI 10.1124/dmd.110.036996
19. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206. DOI 10.1056/NEJMoa1010494
20. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17. DOI 10.1056/NEJMoa1009482
21. US National Institutes of Health. Three-year follow-up of subjects after administration of boceprevir or narlaprevir for the treatment of chronic hepatitis C (P05063AM1). www.clinicaltrials.gov/ct2/show/NCT00689390? term=NCT00689390&rank=1 (accessed 2010 Sep 20).
22. Kwo, PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705-16. DOI 10.1016/S0140-6736(10)60934-8
23. US National Institutes of Health. A Phase 2b, safety and efficacy study of boceprevir in patients coinfected with HIV and hepatitis C (P05411 AM3). www.clinicaltrials.gov/ct2/results?term=NCT00959699 (accessed 2010 Sep 20).
24. Product information. Rebetol (ribavirin). Kenilworth, NJ: Schering Plough, October 2010.
25. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38. DOI 10.1056/NEJMoa0806104
26. Hezode, C, Forestier, N, Dusheiko, G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50. DOI 10.1056/NEJMoa0807650
27. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9. DOI 10.1053/gast.2002.35950
28. Curry S, Qiu P, Tong X. Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay. J Virol Methods 2008;153:156-62. DOI 10.1016/j.jviromet.2008.07.020
29. Susser, S, Welsch, C, Wang, Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009;50:1709-18. DOI 10.1002/hep.23192
30. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006;70:28-38. DOI 10.1016/j.antiviral.2005.12.003
31. Ralston R, Vierling J, Lawitz E, et al. Long-term follow-up of patients treated with boceprevir in combination with PEG-Intron/ribavirin (P/R): durability of responses and rates of reversion of resistance mutations (abstract 22). Presented at: International HIV & Hepatitis Virus Drug Resistance Workshop & Curative Strategies, Dubrovnik, Croatia, 2010.